发明名称 |
PREDICTIVE TEST FOR SELECTION OF METASTATIC BREAST CANCER PATIENTS FOR HORMONAL AND COMBINATION THERAPY |
摘要 |
<p>A mass-spectral method is disclosed for determining whether breast cancer patient is likely to benefit from a combination treatment in the form of administration of a targeted anti-cancer drug in addition to an endocrine therapy drug. The method obtains a mass spectrum from a blood-based sample from the patient. The spectrum is subject to one or more predefined pre-processing steps. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained. The values are used in a classification algorithm using a training set comprising class-labeled spectra and a class label for the sample is obtained. If the class label is "Poor", the patient is identified as being likely to benefit from the combination treatment. In a variation, the "Poor" class label predicts whether the patient is unlikely to benefit from endocrine therapy drugs alone, regardless of the patient's HER2 status.</p> |
申请公布号 |
EP2668504(A1) |
申请公布日期 |
2013.12.04 |
申请号 |
EP20120739078 |
申请日期 |
2012.01.24 |
申请人 |
BIODESIX, INC. |
发明人 |
ROEDER, JOANNA;GRIGORIEVA, JULIA;ROEDER, HEINRICH |
分类号 |
G01N33/574 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|